Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Hospitalized Patients With Severe Coronavirus Disease 2019 During the Omicron Wave in Israel: Benefits of a Fourth Vaccine Dose
Tal Brosh‐Nissimov, Khetam Hussein, Yonit Wiener‐Well, et al.
Clinical Infectious Diseases (2022) Vol. 76, Iss. 3, pp. e234-e239
Open Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study
Niklas Worm Andersson, Emilia Myrup Thiesson, Ulrike Baum, et al.
BMJ (2023), pp. e075286-e075286
Open Access | Times Cited: 64
Awareness of SARS-CoV-2 Omicron Variant Infection Among Adults With Recent COVID-19 Seropositivity
Sandy Joung, Joseph E. Ebinger, Nancy Sun, et al.
JAMA Network Open (2022) Vol. 5, Iss. 8, pp. e2227241-e2227241
Open Access | Times Cited: 44
Estimation of Vaccine Effectiveness of CoronaVac and BNT162b2 Against Severe Outcomes Over Time Among Patients With SARS-CoV-2 Omicron
Yuchen Wei, Katherine Min Jia, Shi Zhao, et al.
JAMA Network Open (2023) Vol. 6, Iss. 2, pp. e2254777-e2254777
Open Access | Times Cited: 28
Outcomes of Elderly Patients Hospitalized with the SARS-CoV-2 Omicron B.1.1.529 Variant: A Systematic Review
Roxana Manuela Fericean, Cristian Oancea, Akash Reddy Reddyreddy, et al.
International Journal of Environmental Research and Public Health (2023) Vol. 20, Iss. 3, pp. 2150-2150
Open Access | Times Cited: 23
Effectiveness of AZD7442 (Tixagevimab/Cilgavimab) for Pre-Exposure Prophylaxis Against COVID-19 Hospitalization in Israel During the Omicron Sub-Variant Time Period
Samah Hayek, Joseph Levy, Galit Shaham, et al.
Infectious Diseases and Therapy (2025) Vol. 14, Iss. 2, pp. 433-445
Open Access
The evolving landscape of COVID-19: factors associated with in-hospital COVID-19 related mortality during the 2023–2024 phase of JN.1 subvariant dominance
Drieda Zaçe, Albiana Çekrezi, Christopher M. Jones, et al.
BMC Infectious Diseases (2025) Vol. 25, Iss. 1
Open Access
COVID-19 and risk of long-term mortality in COPD: a nationwide population-based cohort study
Hyun Lee, Sang Hyuk Kim, Cho Yun Jeong, et al.
BMJ Open Respiratory Research (2025) Vol. 12, Iss. 1, pp. e002694-e002694
Open Access
Protection of the third-dose and fourth-dose mRNA vaccines against SARS-CoV-2 Omicron subvariant: a systematic review and meta-analysis
Obaidur Rahman, Taro Kamigaki, Moe Moe Thandar, et al.
BMJ Open (2023) Vol. 13, Iss. 12, pp. e076892-e076892
Open Access | Times Cited: 14
SARS-CoV-2 breakthrough infections enhance T cell response magnitude, breadth, and epitope repertoire
Alison Tarke, Parham Ramezani-Rad, Tertuliano Alves Pereira Neto, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 6, pp. 101583-101583
Open Access | Times Cited: 4
Effectiveness of a booster dose of COVID-19 vaccines during an outbreak of SARS-CoV-2 Omicron BA.2.2 in China: A case–control study
Xiaqing Zhang, Yao Wang, Cheng‐Yang Hu, et al.
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 1
Open Access | Times Cited: 10
Severity of Omicron Subvariants and Vaccine Impact in Catalonia, Spain
Víctor López de Rioja, Luca Basile, Aida Perramon, et al.
Vaccines (2024) Vol. 12, Iss. 5, pp. 466-466
Open Access | Times Cited: 3
New variants of COVID‐19 (XBB.1.5 and XBB.1.16, the “Arcturus”): A review of highly questioned concerns, a brief comparison between different peaks in the COVID‐19 pandemic, with a focused systematic review on expert recommendations for prevention, vaccination, and treatment measures in the general population and at‐risk groups
Homa Pourriyahi, Nima Hajizadeh, Mina Khosravi, et al.
Immunity Inflammation and Disease (2024) Vol. 12, Iss. 6
Open Access | Times Cited: 3
Personalized Assessment of Mortality Risk and Hospital Stay Duration in Hospitalized Patients with COVID-19 Treated with Remdesivir: A Machine Learning Approach
Antonio Ramón, Andrés Bas, Santiago Herrero, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 7, pp. 1837-1837
Open Access | Times Cited: 2
Booster vaccines dose reduced mortality in hospitalized COVID-19 patients requiring oxygen supplementation: Evidence from the Beijing Omicron outbreak
Xinrui Wang, Yi Zhang, Chong Huang, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 2
Impact of vaccination on the presence and severity of symptoms in hospitalized patients with an infection of the Omicron variant (B.1.1.529) of the SARS-CoV-2 (subvariant BA.1)
Guillaume Béraud, Laura Bouetard, Rok Čivljak, et al.
Clinical Microbiology and Infection (2022) Vol. 29, Iss. 5, pp. 642-650
Open Access | Times Cited: 12
Effectiveness of mRNA vaccine against Omicron-related infections in the real world: A systematic review and meta-analysis
Kaixin Guo, Peng Ni, Shuailei Chang, et al.
American Journal of Infection Control (2023) Vol. 51, Iss. 9, pp. 1049-1055
Closed Access | Times Cited: 7
Epidemiological characteristics of Omicron and Delta SARS-CoV-2 variant infection in Santiago, Chile
Andrea Mella‐Torres, Alejandro Escobar, Carlos Barrera‐Avalos, et al.
Frontiers in Public Health (2022) Vol. 10
Open Access | Times Cited: 11
Incidence of and risk factors for suspected COVID-19 reinfection in Kyoto City: a population-based epidemiological study
Miki Nagao, Yasufumi Matsumura, Masaki Yamamoto, et al.
European Journal of Clinical Microbiology & Infectious Diseases (2023) Vol. 42, Iss. 8, pp. 973-979
Open Access | Times Cited: 6
A Review on the Impact of the SARS-CoV-2 Omicron Subvariant on Elderly Patients with Diverse Co-Morbidities
Avinash Khadela, Shruti Soni, Kaivalya Megha, et al.
Biologics (2023) Vol. 3, Iss. 2, pp. 138-157
Open Access | Times Cited: 6
Risk factors for death and illness severity in vaccinated versus unvaccinated COVID-2019 inpatients: a retrospective cohort study
Guilherme Jorge Costa, José Roberto da Silva, Caio Cesar Arruda da Silva, et al.
Jornal Brasileiro de Pneumologia (2023), pp. e20230145-e20230145
Open Access | Times Cited: 5
Personalized Assessment of Mortality Risk and Hospital Stay Duration in Hospitalized Patients with COVID-19 Treated with Remdesivir: A Machine Learning Approach
Antonio Ramón, Andrés Bas Castillo, Santiago Herrero González, et al.
(2024)
Open Access | Times Cited: 1
Timing of BNT162b2 vaccine prior to COVID‐19 infection, influence disease severity in patients with hematologic malignancies: Results from a cohort study
Odit Gutwein, Katrin Herzog Tzarfati, Arie Apel, et al.
Cancer Medicine (2023) Vol. 12, Iss. 21, pp. 20503-20510
Open Access | Times Cited: 3
Modeling COVID-19 vaccine booster-elicited antibody response and impact of infection history
Takara Nishiyama, Yuichiro Miyamatsu, Hyeongki Park, et al.
Vaccine (2023) Vol. 41, Iss. 52, pp. 7655-7662
Open Access | Times Cited: 2
Deficient Immune Response following SARS-CoV-2 Vaccination in Patients with Hepatobiliary Carcinoma: A Forgotten, Vulnerable Group of Patients
Malte B. Monin, Leona I. Baier, Jens Gabriel Gorny, et al.
Liver Cancer (2023) Vol. 12, Iss. 4, pp. 339-355
Open Access | Times Cited: 2
Incidence of COVID-19 mRNA vaccine symptomatic breakthrough infections during Omicron circulation in adults with or without infection prior to vaccination
Christine Durier, Läétitia Ninove, Sylvie van der Werf, et al.
Infectious Diseases Now (2024) Vol. 54, Iss. 5, pp. 104886-104886
Open Access
Page 1 - Next Page

Scroll to top